{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:31:58Z","timestamp":1786653118774,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung India"],"published-print":{"date-parts":[[2015]]},"DOI":"10.4103\/0970-2113.168135","type":"journal-article","created":{"date-parts":[[2015,10,27]],"date-time":"2015-10-27T00:59:18Z","timestamp":1445907558000},"page":"620","source":"Crossref","is-referenced-by-count":6,"title":["Rituximab-induced interstitial lung disease in a patient with follicular lymphoma: A rare case report"],"prefix":"10.4103","volume":"32","author":[{"given":"Suhas","family":"Aagre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurva","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradip","family":"Kendre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0970-2113.168135-1","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"key-10.4103\/0970-2113.168135-2","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/pds.1587","article-title":"Post-marketing safety of antineoplasic monoclonal antibodies: Rituximab and trastuzumab","author":"Gonz\u00e1lez","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key-10.4103\/0970-2113.168135-3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomized controlled trial","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"key-10.4103\/0970-2113.168135-4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: Systematic review and meta-analysis of randomized trials","author":"Vidal","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/0970-2113.168135-5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/160421","article-title":"Rituximab induced interstitial lung disease in patients with non-hodgkin's lymphoma: A clinical study of six cases and review of the literature","author":"Krishnaswamy","year":"2014","journal-title":"Lymphoma"},{"key":"key-10.4103\/0970-2113.168135-6","first-page":"2690","article-title":"Interstitial pneumonitis related to rituximab therapy","author":"Burton","year":"2003","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0970-2113.168135-7","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/rheumatology\/ker290","article-title":"Non-infectious pulmonary toxicity of rituximab: A systematic review","author":"Hadjinicolaou","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"key-10.4103\/0970-2113.168135-8","first-page":"v1","article-title":"; British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of Care Committee; Thoracic Societyof Australia; New Zealand Thoracic Society; Irish Thoracic Society.Interstitial lung disease guideline: The British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society","author":"Bradley","year":"2008","journal-title":"Thorax"},{"key":"key-10.4103\/0970-2113.168135-9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1183\/09031936.00080209","article-title":"Rituximab induced lung disease: A systematic literature review","author":"Liot\u00e9","year":"2010","journal-title":"Eur Respir J"},{"key":"key-10.4103\/0970-2113.168135-10","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1080\/10428190802270886","article-title":"Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma","author":"Liu","year":"2008","journal-title":"Leuk Lymphoma"}],"container-title":["Lung India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:31:49Z","timestamp":1786649509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0970-2113.168135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015]]}},"alternative-id":["168135"],"URL":"https:\/\/doi.org\/10.4103\/0970-2113.168135","relation":{},"ISSN":["0970-2113"],"issn-type":[{"value":"0970-2113","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}